Code Corporation Enables Epic Rover Mobile Barcode Reading Capabilities for Mass COVID-19 Vaccination Rollout
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Code is offering a 6-month free demo license of CortexDecoder for Epic Rover customers that enables healthcare facilities to speed vaccination efforts
SALT LAKE CITY--(BUSINESS WIRE)-- Code Corporation, a global leader in barcode scanning and data capture technologies, has collaborated with Epic, developer of the leading electronic health record system (EHR), to offer mobile scanning capabilities through Code’s CortexDecoder software. To support health systems mass COVID-19 vaccination effort, Code is offering a free six-month demo license to users of the Rover mobile app, which will help them get up and running as quickly as possible.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005905/en/
Code offers a 6-month free demo license of CortexDecoder for Epic Rover customers that enables healthcare facilities to speed vaccination efforts (Graphic: Business Wire)
“By scanning and reading barcodes, Code serves as the bridge between the patients seeking vaccinations and their vaccination appointments in the EMR powering the mass COVID-19 vaccination rollout,” Kent Hansen, CEO of Code Corporation said. “Code’s CortexDecoder can be accessed in Rover, enabling healthcare professionals to quickly find and open a patient chart to help move the patient through the vaccination process. With CortexDecoder healthcare, workers can quickly and accurately read any applicable barcodes right from their mobile device to speed the process of mass immunization.”
CortexDecoder is an enterprise-grade barcode decoder technology that allows users to decode any barcode symbology. It can read barcodes of virtually any print quality, at any angle, on any surface—including curved or reflective surfaces, and can even handle damaged barcodes.
CortexDecoder within Rover is a module used to decode barcodes. It is a fast and reliable decoder available to Rover customers. CortexDecoder does not store or transfer any data to any outside source for any reason. When barcodes are scanned, it simply decodes the barcode and immediately sends the decoded data into Rover for use, making it the most secure option available.
This level of security and accuracy empowers organizations with streamlined efficiency where it is needed most. Coupling security, accuracy and efficiency with hand-held mobility enables the seamless coordination of mass immunization efforts in traditional and non-traditional care settings, such as hospitals or drive-through vaccination centers.
Customers of Epic may access the six-month demo license to CortexDecoder through this site: https://www.codecorp.com/covidvax.
About Code Corporation
For more than 20 years, Code Corporation has been an industry pioneer, leader, and champion for data capture innovation and has garnered more than 100 patents. By crafting and continuing to perfect its unique decoding algorithms, Code and its line of image-based scanning and decoding technology consistently deliver unparalleled performance companies around the world depend on every day. Code designs and manufactures a complete line of market-leading hardware and software data capture solutions. Code products are not only valued for providing a consistent level of workflow efficiency year after year, but also for their ergonomic design, durability, ease of customization, and seamless integration. For more, please visit www.codecorp.com.
Sal Giani, Marketing Manager
Source: Code Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recu
- GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model
- Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting